TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34903983
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline 150 mL
Study: 34903983
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups received 250 mg IV furosemide every 12 h for 48 h
Study: 32487038
Drug: Stereotactic ablative
Normalized name: ABL
DrugBank: Lauric acid (DB03017)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stereotactic ablative radiation (SABR) + radium-223 dichloride (6 infusions at 4-week intervals)
Study: 34556166
Drug: Single-dose intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose intravenous iron (two different formulations) administered early in the second trimester
Study: 34556166
Drug: Standard doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard doses of oral iron
Study: 34556166
Drug: Single-dose intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose intravenous iron (two different formulations)
Study: 32880105
Drug: Phenytoin (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenytoin (300 mg/day)
Study: 33491093
Drug: Pulsed dye
Normalized name: amaranth dye
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulsed dye laser‐mediated photodynamic therapy
Study: 33491093
Drug: Conventional red‐light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional red‐light photodynamic therapy
Study: 36380126
Drug: Early withdrawal
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early withdrawal of life-sustaining treatments based on presumed poor neurologic prognosis (WLST-N)
Study: 36380126
Drug: Use of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Use of sedative medications in patients with early WLST-N
Study: 32641081
Drug: Preoperative immunonutrition
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative immunonutrition (400 mL/day with arginine and ω‐3 fatty acids for 7 days)
Study: 34942330
Drug: Multivitamin/Mineral Supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multivitamin/Mineral Supplement (MVM)
Study: 34942330
Drug: No study‐provided
Approvals — FDA: no, EMA: no, PMDA: no
Description: No study‐provided supplements
Study: 34229859
Drug: Morphine (0.02
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine (0.02 mg.kg‐1.h‐1)
Study: 34229859
Drug: Fentanyl (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl (0.3 mcg.kg‐1.h‐1)
Study: 34229859
Drug: Both Morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both Morphine and Fentanyl
Study: 32343918
Drug: Subcutaneous lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subcutaneous lidocaine infusion (SCLI) at a dosage of 10 mg/kg over 5.5 hours
Study: 35210767
Drug: Oral antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral antibiotics prescribed in the prior 12 months
Study: 35871473
Drug: Topical 4%
Normalized name: menthol topical 4% topical gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 4% sucralfate cream four times a day for 2 months
Study: 34508901
Drug: Atomoxetine (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atomoxetine (40 mg)
Study: 34882608
Drug: Novel combination
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Novel combination of omega‐3 and omega‐6 fatty acids (1200 mg eicosapentaenoic acid, 300 mg docosahexaenoic acid, 150 mg γ‐linoleic acid)
Study: 34882608
Drug: Novel combination
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Novel combination of omega‐3 and omega‐6 fatty acids
Study: 32779011
Drug: GC dry
Normalized name: ARTIFICIAL SALIVA GC DRY MOUTH DENT GEL
Approvals — FDA: no, EMA: no, PMDA: no
Description: GC dry mouth gel (GC)
Study: 32444040
Drug: Aq+ (3056
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aq+ (3056 mg day-1)
Study: 32444040
Drug: Glu (2000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glu (2000 mg day-1)
Study: 34868084
Drug: Leronlimab (weekly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leronlimab (weekly 700 mg)
Study: 34868084
Drug: Leronlimab (weekly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leronlimab (weekly treatment)
Study: 32901330
Drug: Fruquintinib (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fruquintinib (5 mg once daily for 3 weeks, followed by 1 week off in 28-day cycles)
Study: 35343430
Drug: New sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: New sodium valproate formulation (epilenil 500‐mg coated tablet)
Study: 35343430
Drug: Depakene formulation
Normalized name: Depakote
DrugBank: Valproic acid (DB00313)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Depakene formulation
Study: 33118638
Drug: Integrative Cognitive‐Affective
Approvals — FDA: no, EMA: no, PMDA: no
Description: Integrative Cognitive‐Affective Therapy for BED
Study: 33118638
Drug: Cognitive‐behavioral therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive‐behavioral therapy delivered using guided self‐help
Study: 33619171
Drug: m276-SL-PBD (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: m276-SL-PBD (0.5 mg/kg on days 1, 8, and 15)
Study: 33619171
Drug: m276-SL-PBD (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: m276-SL-PBD (single 0.5 mg/kg dose)
Study: 37090440
Drug: Moderate-intensity statin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate-intensity statin with ezetimibe combination therapy (rosuvastatin 10 mg with ezetimibe 10 mg)
Study: 37495276
Drug: High-intensity statin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-intensity statin monotherapy (rosuvastatin 20 mg)
Study: 37978309
Drug: Moderate-intensity statin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate-intensity statin with ezetimibe combination therapy
Study: 36529993
Drug: High-intensity statin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-intensity statin monotherapy
Study: 35780241
Drug: Weekly educational
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly educational one-way text messages on sexo-reproductive health
Study: 32427354
Drug: Intraduodenal infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intraduodenal infusion of voriconazole (VRZ) at 7.5 mg/h from 8 to 16 hours and 15 mg/h from 16 to 24 hours combined with midazolam (MDZ) at 0.26 mg/h for 24 hours
Study: 32427354
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of voriconazole (VRZ) at 7.5 mg/h from 8 to 16 hours and 15 mg/h from 16 to 24 hours combined with midazolam (MDZ) at 0.26 mg/h for 24 hours
Study: 33308274
Drug: Capsaicin application
Normalized name: Capsaicin
DrugBank: Capsaicin (DB06774)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Capsaicin application (depth and dose not specified)
Study: 33308274
Drug: Placebo (control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (control treatment groups)
Study: 33516143
Drug: KXS 3.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: KXS 3.2 g/day
Study: 35022282
Drug: Celecoxib 200
Normalized name: celecoxib 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celecoxib 200 mg twice daily plus FOLFIRI regimen (5-fluorouracil, leucovorin, irinotecan)
Study: 34899124
Drug: Behavioural therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioural therapy (biofeedback training)
Study: 35589610
Drug: Ladarixin (LDX)
Normalized name: Ladarixin
DrugBank: Ladarixin (DB16212)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ladarixin (LDX) 400 mg twice-daily for three cycles of 14 days on/14 days off
Study: 33130034
Drug: Control (HICT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (HICT performed twice at baseline and end)
Study: 39539565
Drug: Aquablation therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aquablation therapy
Study: 32200225
Drug: Treatment targeting
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment targeting reductions in negative affect or increases in positive affect (15 sessions)
Study: 33942327
Drug: Convalescent plasma
Normalized name: Convalescent plasma
DrugBank: COVID-19 convalescent plasma (DB15692)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Convalescent plasma therapy (CPT), median volume of 828 ml (range: 817–960), administered 14 days after ICU admission.
Study: 34930267
Drug: Cipargamin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cipargamin (10 to 150 mg single doses and 10 to 50 mg once daily for 3 days)
Study: 36905719
Drug: Mevidalen 10
Normalized name: Mevidalen
DrugBank: Mevidalen (DB19034)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mevidalen 10 mg
Study: 36905719
Drug: Mevidalen 30
Normalized name: Mevidalen
DrugBank: Mevidalen (DB19034)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mevidalen 30 mg
Study: 36905719
Drug: Mevidalen 75
Normalized name: Mevidalen
DrugBank: Mevidalen (DB19034)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mevidalen 75 mg
Study: 33523774
Drug: Budesonide intranasal
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide intranasal formulation with charcoal block
Study: 33523774
Drug: Budesonide intranasal
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide intranasal formulation without charcoal block
Study: 32073622
Drug: Manual pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual pill counting using a plastic dish and spatula
Study: 32073622
Drug: Efforts put
Approvals — FDA: no, EMA: no, PMDA: no
Description: Efforts put into pill counting
Study: 32073622
Drug: Interventions alleviating
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interventions alleviating the burden of pill counting
Study: 33673587
Drug: Almonds (20%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Almonds (20% of daily energy consumption)
Study: 32391667
Drug: Hydroxychloroquine (HCQ)
DrugBank: Hydroxychloroquine (DB01611)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydroxychloroquine (HCQ) 400 mg per day for 5 days plus conventional treatments
Study: 34229330
Drug: Protease inhibitor
Normalized name: Protease inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protease inhibitor resistance
Study: 35579297
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline infusion at a rate of 125 mL/h
Study: 35579297
Drug: 1/3-2/3 infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1/3-2/3 infusion at a rate of 125 mL/h
Study: 35579297
Drug: Ringer's lactate
Normalized name: Ringer's lactate/gel dressing 2.2" TOPICAL KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ringer's lactate infusion at a rate of 125 mL/h
Study: 36096824
Drug: Magnesium citrate
Normalized name: Magnesium Citrate
DrugBank: Magnesium (DB14513)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Magnesium citrate (350 mg elemental magnesium/day)
Study: 36096824
Drug: Phosphate binder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phosphate binder sucroferric oxyhydroxide (1000 mg/day)
Study: 33979464
Drug: Xiyanping injection
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Xiyanping injection in combination with standard therapy
Study: 33979464
Drug: Standard supportive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard supportive therapy alone
Study: 34288256
Drug: Glide-path preparation
Normalized name: Chamois Glide
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glide-path preparation
Study: 34485157
Drug: Endostar continuous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endostar continuous intravenous infusion of anti‐angiogenic therapy plus CCRT
Study: 34485157
Drug: Radiotherapy for
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Radiotherapy for cervical cancer and paclitaxel combined with platinum chemotherapy (CCRT)
Study: 32600386
Drug: radial extracorporeal
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: radial extracorporeal shock wave therapy (rESWT)
Study: 34080077
Drug: Oral danirixin
Normalized name: Danirixin
DrugBank: Danirixin (DB11922)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral danirixin 75 mg twice daily
Study: 32473084
Drug: Topical active
Normalized name: collagen,activated Topical Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical active lotion (Redensyl and Sepicontrol A5), applied twice daily for 24 weeks
Study: 32473084
Drug: Vehicle control,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle control, applied twice daily for 24 weeks
Study: 36269028
Drug: 5% lidocaine
Normalized name: LIDOCAINE 5 g in 100 g TOPICAL CREAM [Healcome Tattoo Numbing Cream 5% Lidocaine]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% lidocaine + 0.5 mg/ml 0.02% oestradiol compound cream + oral placebo pill
Study: 36269028
Drug: Tricyclic antidepressant
Normalized name: Tricyclic antidepressant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tricyclic antidepressant nortriptyline + placebo cream
Study: 36269028
Drug: Combined peripheral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined peripheral cream and central pill treatments
Study: 36269028
Drug: Placebo cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo cream and placebo pill
Study: 33150360
Drug: Truncated asparaginase
Normalized name: Asparaginase
DrugBank: Asparaginase Erwinia chrysanthemi (DB08886)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Truncated asparaginase treatment due to clinical toxicity (n = 358)
Study: 33150360
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment without truncation (n = 1043)
Study: 33150360
Drug: Truncated asparaginase
Normalized name: Asparaginase
DrugBank: Asparaginase Erwinia chrysanthemi (DB08886)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Truncated asparaginase treatment or silent inactivation (n = 301)
Study: 35614156
Drug: Losartan ointment
DrugBank: Losartan (DB00678)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Losartan ointment
Study: 33651470
Drug: Water-soluble herbal
Normalized name: WATER SOLUBLE BASE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Water-soluble herbal acne patch (WHAP)
Study: 33651470
Drug: Hydrocolloid acne
Normalized name: Propionibacterium acnes
DrugBank: Propionibacterium acnes (DB19089)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrocolloid acne patch (HAP)
Study: 33182295
Drug: Pre-workout supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-workout supplement
Study: 33725178
Drug: VC+ group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: VC+ group (500 mg/day PO for 45 days postoperatively)
Study: 32299454
Drug: Combined extracorporeal
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined extracorporeal shock wave lithotripsy (ESWL) and endoscopic treatment
Study: 32299454
Drug: Combined ESWL
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined ESWL and endoscopic treatment
Study: 36027559
Drug: Acetazolamide (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetazolamide (500 mg once daily)
Study: 32443298
Drug: low-dose recombinant
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: low-dose recombinant tissue plasminogen activator (rt-PA)
Study: 35490744
Drug: Lenabasum (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lenabasum (20 mg daily for 28 days, then 20 mg twice per day for 56 days)
Study: 38160885
Drug: Paroxetine treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paroxetine treatment for 4 weeks
Study: 32725069
Drug: Fungicide treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fungicide treatment FT1 (pyraclostrobin + fluxapyroxad)
Study: 32725069
Drug: Fungicide treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fungicide treatment FT2 (trifloxystrobin + prothioconazole)
Study: 34333889
Drug: Guided Self-Determination
Normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Guided Self-Determination (GSD) intervention with weekly sessions for eight weeks
Study: 35813843
Drug: Caffeine (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (3 mg/kg/b.m.)
Study: 32133542
Drug: Mud-bath therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mud-bath therapy using clay peloid mixed with tap water and heliotherapy (group 2)
Study: 35538143
Drug: anthracycline/taxane‐based NACT
Approvals — FDA: no, EMA: no, PMDA: no
Description: anthracycline/taxane‐based NACT plus metformin
Study: 35725488
Drug: 2-dose Ebola
Normalized name: Zaire ebolavirus envelope glycoprotein Injection [Ervebo]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-dose Ebola vaccine regimen (Ad26.ZEBOV, MVA-BN-Filo)
Study: 32178279
Drug: EPA-rich fish
Approvals — FDA: no, EMA: no, PMDA: no
Description: EPA-rich fish oil (12 g/day, EPA/DHA: 2.3)
Study: 32178279
Drug: DHA-rich fish
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHA-rich fish oil (12 g/day, EPA/DHA: 0.3)
Study: 35398293
Drug: Daily teriparatide
Normalized name: Teriparatide
DrugBank: Teriparatide (DB06285)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Daily teriparatide (20 μg)
Study: 35398293
Drug: Weekly high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly high-dose teriparatide (56.5 μg)
Study: 35287618
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g of tranexamic acid (TXA) 15 minutes before surgery
Study: 33577729
Drug: Enfortumab vedotin
Normalized name: ENFORTUMAB VEDOTIN
DrugBank: Enfortumab vedotin (DB13007)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Enfortumab vedotin (1.25 mg/kg on days 1, 8, and 15 of a 28-day cycle)
Study: 33577729
Drug: Chemotherapy (investigator-chosen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (investigator-chosen standard docetaxel, paclitaxel, or vinflunine on day 1 of a 21-day cycle)
Study: 38182785
Drug: Ripretinib 150
Normalized name: Ripretinib
DrugBank: Ripretinib (DB14840)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Ripretinib 150 mg once daily
Study: 37598656
Drug: Sunitinib 50
Normalized name: sunitinib 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sunitinib 50 mg once daily (4 weeks on/2 weeks off)
Study: 36382669
Drug: 0.025% capsaicin
Normalized name: CAPSAICIN 2.5 mg in 10 g TOPICAL PATCH [0.025% Capsaicin Patch]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.025% capsaicin gel with topical anesthetic
Study: 36382669
Drug: Topical anesthetic
Normalized name: Topical anesthetic
DrugBank: Benzocaine (DB01086)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical anesthetic monotherapy
Study: 34037975
Drug: Oral sucrose
Normalized name: TootSweet 24% Oral Sucrose Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral sucrose solution (2 ml)
Study: 32144874
Drug: Standard adherence
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard adherence support (counselling, two-way SMS, monthly adherence clubs)
Study: 32144874
Drug: Standard support
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard support plus drug-level feedback
Study: 32144874
Drug: Standard adherence
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard adherence support and drug-level feedback
Study: 33938520
Drug: Antipsychotic-naive participants
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antipsychotic-naive participants
Study: 33938520
Drug: Participants previously
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants previously exposed to antipsychotics
Study: 35920410
Drug: Topical 10%
Normalized name: urea topical 10% topical cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 10% lidocaine cream
Study: 35920410
Drug: 10% lidocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% lidocaine cream
Study: 33638644
Drug: Feedback on
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: Feedback on quantity of antibiotic use (DDD, days-of-therapy)
Study: 33242835
Drug: Durvalumab therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Durvalumab therapy following chemoradiation
Study: 36375188
Drug: Septum-based double
Approvals — FDA: no, EMA: no, PMDA: no
Description: Septum-based double injection (DI group)
Study: 36375188
Drug: Single injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single injection (SI group)
Study: 36127497
Drug: SGLT2 inhibitor
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SGLT2 inhibitor (SGLT2i) treatment for 12 weeks
Study: 34931289
Drug: Intraoperative infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intraoperative infusion of dexmedetomidine 0.4 μg·kg‐1·hr‐1
Study: 34931289
Drug: Intraoperative infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intraoperative infusion of dexmedetomidine
Study: 32873686
Drug: TEXT4BP intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: TEXT4BP intervention (text messages containing information on hypertension, diet, medication and physical activity three times a week for 3 months)
Study: 35114409
Drug: Potential treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Potential treatment mechanisms (self-efficacy, motivation, treatment engagement)
Study: 34467593
Drug: Vonafexor 400
Normalized name: Vonafexor
DrugBank: Vonafexor (DB18782)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vonafexor 400 mg once daily
Study: 34467593
Drug: Vonafexor 200
Normalized name: Vonafexor
DrugBank: Vonafexor (DB18782)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vonafexor 200 mg twice daily
Study: 34467593
Drug: Vonafexor/pegylated-IFN-?2a combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vonafexor/pegylated-IFN-?2a combination therapy
Study: 33837797
Drug: Radiofrequency (RF)
Normalized name: Aminosyn-RF 5.2 %, Sulfite-Free
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiofrequency (RF) treatment consisting of three monthly sessions
Study: 33837797
Drug: Pelvic floor
Normalized name: Tenscare Kegel Toner Pelvic Floor Trainer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pelvic floor muscle training (PFMT) consisting of 12 weekly sessions
Study: 33837797
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of RF + PFMT
Study: 34798853
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg MPH + 10 mg escitalopram
Study: 34798853
Drug: Placebo +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo + 10 mg escitalopram